Novo Nordisk A/S

The momentum for this stock is not very good. Novo Nordisk A/S has good growth characteristics. Novo Nordisk A/S is not very popular among insiders. Novo Nordisk A/S is a mediocre stock to choose.
Log in to see more information.
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, a...
NVO Fundamental Data by TradingView

News

MGO One Seven LLC Has $2.83 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)
MGO One Seven LLC Has $2.83 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Zolmax MGO One Seven LLC increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 22.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities...\n more…

MGO One Seven LLC Acquires 3,629 Shares of Novo Nordisk A/S (NYSE:NVO)
MGO One Seven LLC Acquires 3,629 Shares of Novo Nordisk A/S (NYSE:NVO)

Ticker Report MGO One Seven LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 22.4% in the second quarter, HoldingsChannel reports. The institutional investor owned 19,799 shares of...\n more…

Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

Zacks Investment Research Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting.CT-996 is an investigational...\n more…

Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now

Yahoo! Finance: News Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now...\n more…

Weight-loss drugs and children: What doctors say about the safety, effectiveness of the medications
Weight-loss drugs and children: What doctors say about the safety, effectiveness of the medications

FOXBusiness.com There is a divide among some physicians about if and when children should use weight-loss drugs, which have surged in popularity among adults. In a recent study published in the New England Journal...\n more…

Roche stock is falling after report its Wegovy challenger is causing patients to vomit
Roche stock is falling after report its Wegovy challenger is causing patients to vomit

Fortune Positive results in the early stages of Roche's weight-loss pill development had given investors hope it could quickly catch up with rivals Novo Nordisk and Eli Lilly. Read More...\n more…